X
Xavier Gonzalez-Farre
Researcher at University of Barcelona
Publications - 11
Citations - 520
Xavier Gonzalez-Farre is an academic researcher from University of Barcelona. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 4, co-authored 4 publications receiving 469 citations.
Papers
More filters
Journal ArticleDOI
Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity.
Vanessa Almendro,Yu-Kang Cheng,Amanda Randles,Amanda Randles,Shalev Itzkovitz,Shalev Itzkovitz,Andriy Marusyk,Andriy Marusyk,Elisabet Ametller,Xavier Gonzalez-Farre,Montse Muñoz,Hege G. Russnes,Hege G. Russnes,Åslaug Helland,Åslaug Helland,Inga H. Rye,Inga H. Rye,Anne Lise Børresen-Dale,Anne Lise Børresen-Dale,Reo Maruyama,Reo Maruyama,Alexander van Oudenaarden,Alexander van Oudenaarden,Mitchell Dowsett,Robin L. Jones,Robin L. Jones,Jorge S. Reis-Filho,Jorge S. Reis-Filho,Pere Gascón,Mithat Gonen,Franziska Michor,Kornelia Polyak +31 more
TL;DR: In this paper, the authors report the analysis of cellular heterogeneity for genetic and phenotypic features and their spatial distribution in breast tumors pre- and post-neoadjuvant chemotherapy.
Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity
Vanessa Almendro,Yu-Kang Cheng,Amanda Randles,Shalev Itzkovitz,Andriy Marusyk,Elisabet Ametller,Xavier Gonzalez-Farre,Hege G. Russnes,Inga H. Rye,Anne Lise Børresen-Dale,Reo Maruyama,Alexander van Oudenaarden,Mitchell Dowsett,Robin L. Jones,Jorge S. Reis-Filho,Pere Gascón,Franziska Michor,Kornelia Polyak,Montse Muñoz,Åslaug Helland,Mithat Gonen +20 more
TL;DR: The analysis of cellular heterogeneity for genetic and phenotypic features and their spatial distribution in breast tumors pre- and post-neoadjuvant chemotherapy found that intratumor genetic diversity was tumor-subtype specific, and it did not change during treatment in tumors with partial or no response.
Journal ArticleDOI
Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer.
Susana García-Recio,Gemma Fuster,Patricia Fernández-Nogueira,Eva María Pastor-Arroyo,So Yeon Park,Cristina Mayordomo,Elisabet Ametller,Mario Mancino,Xavier Gonzalez-Farre,Hege G. Russnes,Pablo Engel,Domiziana Costamagna,Pedro L. Fernández,Pedro Gascón,Vanessa Almendro +14 more
TL;DR: This work reveals an important oncogenic cooperation between NK-1R and HER2, thereby adding a novel link between inflammation and cancer progression that may be targetable by SP antagonists that have been clinically explored.
Journal ArticleDOI
SEOM clinical guidelines in early-stage breast cancer 2015.
José A. García-Sáenz,Begoña Bermejo,Laura G. Estévez,A. G. Palomo,Xavier Gonzalez-Farre,Mireia Margeli,Sonia Pernas,Sonia Servitja,César A. Rodríguez,Eva Ciruelos +9 more
TL;DR: Current evidence for the medical management of early-stage breast cancer is summarized in these guidelines to select the most appropriate adjuvant therapy in each patient.
Journal ArticleDOI
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
Guy Jerusalem,Yeon Hee Park,Sara A. Hurvitz,Shanu Modi,Fabrice Andre,Ian E. Krop,Xavier Gonzalez-Farre,Benoit You,Cristina Saura,Sung-Bae Kim,CK Osborne,Rashmi Krishna Murthy,Lorenzo Gianni,Toshimi Takano,Yali Liu,Jillian Cathcart,Caleb Lee,Christophe Perrin +17 more
TL;DR: The safety profile of TDXd was consistent with previous studies, and the durable clinical activity of T DXd in this population warrants further investigation.